Mathijs Sanders

Researcher, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Visiting post-doc Sanger Institute, Cambridge, UK.

[Mathijs Sanders @MathijsSanders]

Extremely grateful for receiving the EHA advanced research grant!

Looking forward delving deeper into the disease mechanisms underlying AML.

Congratulations to all EHA award winners!

#EHA2024 @EHA_Hematology @ErasmusMC @erasmusmcblood

[Mathijs Sanders @MathijsSanders]

Interested in the construction of high performance computing clusters? Do you have affinity with scientific computing and AI research?

The Erasmus MC is looking for a Senior Engineer to help build its state-of-the-art HPC cluster.

@ErasmusMC #HPC #IT

https://t.co/fLONHOMBss

[Jamie Blundell @jrblundell]

Delighted to share our latest on longitudinal methylation dynamics preceding cancer. Epigenetic signs of AML appear in blood DECADES before Dx. By brilliant @__AFonseca

✅Early cancer
✅Methylation drivers
✅Epimutation rates
✅CpG lineage tracing

https://t.co/7GcXeSGuhP

[Blood Cancer Discovery @BCD_AACR]

Read the commentary: Putting AML Differentiation States on the BoneMarrowMap, by Jonas Berger and Livius Penter, online now concurrent with #AACR25. https://t.co/OeooE4WCcy

[Heng Li @lh3lh3]

longcallD is a new variant caller for genomic long reads. It jointly calls phased small and structural variants. Single binary, one command line for the whole process. Comparable accuracy to mainstream callers. Great work by Yan Gao. https://t.co/ARWQ4TzfR5

[Tim Coorens @TimCoorens]

The stomach is an organ unique in its function, environment and exposures. How does this affect the mutations that normal cells in the stomach acquire? What does this reveal about the origins of stomach cancer? These questions and more in our Nature paper:
https://t.co/n7vcJq0ApW

[European Hematology Association @EHA_Hematology]

Applications for #TRTH2026 are now open!
Are you an early-career researcher in translational hematology? The EHA-ASH TRTH program provides a unique opportunity to enhance your research skills with guidance from leading international experts.

🔹 Applications open today, March 15!
🔹 Deadline: June 26, 2025, at 11:59 PM ET

Don’t miss this chance to advance your career in hematology research. Apply now!
Learn more: https://t.co/diy1y1aUFg
Apply now: https://t.co/obTrl2yGwi

#HematologyResearch #CareerDevelopment #TRTH #TRTH2026

[Mathijs Sanders @MathijsSanders]

@SylvieNoorderm1 Congrats Sylvie!!

[Mathijs Sanders @MathijsSanders]

@EarlyCancerCam @jrblundell Congratulations Jamie! Well-deserved!

[Ruud Delwel @DelwelRuud]

07 October 2024 at 16.00 CET
Erasmus Hematology Virtual Lecture.
We have:
Kellie Machlus, Boston Children’s , with
"Unraveling roles for megakaryocytes beyond platelet production through novel model systems"
Spread the news!
https://t.co/ICOMFc5jv5
@theclotthickens

[Mathijs Sanders @MathijsSanders]

Today, we have Alexander Bick presenting! Don't miss it.

23 September at 16.00 CET
Title: "Clonal hematopoiesis: causes, consequences and management"
Link: https://t.co/CQxwcKkRR1

[Mathijs Sanders @MathijsSanders]

@JurjenVersluis @JCO_ASCO Congrats Jurjen!

[Jurjen Versluis @JurjenVersluis]

Excited to share our latest study in @JCO_ASCO on improving risk stratification for older patients (≥60 yrs) with Acute Myeloid Leukemia (AML)!
We developed a novel prognostic model: AML60+. #Leukemia #AML link: https://t.co/8TM1pS3FdC
🧵1/9

[William J. Greenleaf @WJGreenleaf]

Our single-cell, pan-cancer analysis of open chromatin in human cancers, done in collaboration with TCGA and the Chang and Corces labs (among others including Illumina), is out in Science today. Congrats to Laksshman Sundaram and all authors! https://t.co/4whYsPvqyN

[Mathijs Sanders @MathijsSanders]

New review by @sjfhermans, @niek_maas, @JurjenVersluis and others, detailing how real-world data can be of added value if collected and used appropriately!

[Niek van der Maas @niek_maas]

New paper out in @JAMAOnc! 🚨

Real-world data (RWD) external control arms are gaining traction in prospective studies, but we need to balance their advantages with meeting evidentiary standards

Our review highlights significant differences between RWD and trial data🧵(1/7)

[Mathijs Sanders @MathijsSanders]

@PeterLyLab @CellCellPress @UTSWGradSchool @JustinEngel17 Congratulations @PeterLyLab and @JustinEngel17, well-deserved!!!

[Peter Ly @PeterLyLab]

🚨 Excited to share our latest paper in @CellCellPress identifying how under-replicated chromosomes in micronuclei become shattered by the Fanconi anemia pathway during mitosis. This work was led by @UTSWGradSchool student @JustinEngel17. 🧵 (1/13):
https://t.co/ixa2y6oAQQ

[Heather Machado @heatherEmachado]

Join us! The Machado Lab at @Cambridge_Uni is looking for an enthusiastic RA to be a core member of the team and lead the lab's data generation efforts, seeking to understand how tumour and immune cells co-evolve and contribute to cancer progression. https://t.co/JSH7AfJfes

[Mathijs Sanders @MathijsSanders]

@PolonenPetri @CMullighan @Nature Congratulations Petri!! Wonderful work!

[Petri Pölönen @PolonenPetri]

Interested in non-coding alterations, large-scale genomics, leukemia? Collaboration between @CMullighan and Teachey labs.

Genomic analysis of >1300 WGS/WTS/WES samples from T-lineage acute lymphoblastic leukemia, out now in @Nature

https://t.co/dMfW9JwlGc

Highlights (7):

[Inigo Martincorena @imartincorena]

Peter Campbell leaves the Sanger Institute at the end of the year to become Quotient's CSO. A mentor and one of my favourite scientists. His foundational, profound and creative contributions to cancer genomics and somatic evolution have truly shaped those fields. [1/7]